Drug Discovery

Follow this topic Ask about this topic

Drug discovery aims to find and develop molecules that act on disease-relevant targets or biological processes, while balancing efficacy, safety, and the ability to make them. AI methods include graph and 3D models for predicting molecular properties, binding, and toxicity; generative models for proposing or editing molecules; and knowledge graphs and omics models for prioritizing targets and interpreting biological responses. Search and design methods increasingly combine these predictions with docking, synthesis constraints, experimental data, and tools coordinated by AI agents. A central challenge is that strong results on standard benchmarks may not transfer to unseen targets, chemistry, or assays, and computational scores still need reliable experimental validation.

Latest papers

164 papers23 papers in the last four weeks, up 156% on the four weeks before. 0.1% of all new papers.

Apr 22, 2026

Mol-Debate: Multi-Agent Debate Improves Structural Reasoning in Molecular Design

Text-guided molecular design is a key capability for AI-driven drug discovery, yet it remains challenging to map sequential natural-language instructions with non-linear molecular structures under strict chemical constraints. Most existing approaches, including RAG, CoT prompting, and fine-tuning or RL, emphasize a small set of ad-hoc reasoning perspectives implemented in a largely one-shot generation pipeline. In contrast, real-world drug discovery relies on dynamic, multi-perspective critique and iterative refinement to reconcile semantic intent with structural feasibility. Motivated by this, we propose Mol-Debate, a generation paradigm that enables such dynamic reasoning through an iterative generate-debate-refine loop. We further characterize key challenges in this paradigm and address them through perspective-oriented orchestration, including developer-debater conflict, global-local structural reasoning, and static-dynamic integration. Experiments demonstrate that Mol-Debate achieves state-of-the-art performance against strong general and chemical baselines, reaching 59.82% exact match on ChEBI-20 and 50.52% weighted success rate on S

^2

-Bench. Our code is available at https://github.com/wyuzh/Mol-Debate.

Wengyu Zhang, Xiao-Yong Wei, Qing Li

♠The Hong Kong Polytechnic University · ♡Sichuan University

AI-Assisted Scientific Research Multi-Agent Debate Molecular Generation Drug Discovery Molecule Design

Apr 21, 2026

Multi-Objective Reinforcement Learning for Generating Covalent Inhibitor Candidates

Rational design of covalent inhibitors requires simultaneously optimizing multiple properties, such as binding affinity, target selectivity, or electrophilic reactivity. This presents a multi-objective problem not easily addressed by screening alone. Here we present a machine learning pipeline for generating covalent inhibitor candidates using multi-objective reinforcement learning (RL), applied to two targets: epidermal growth factor receptor (EGFR) and acetylcholinesterase (ACHE). A SMILES-based pretrained LSTM serves as the generative model, optimized via policy gradient RL with Pareto crowding distance to balance competing scoring functions including synthetic accessibility, predicted covalent activity, residue affinity, and an approximated docking score. The pipeline rediscovers known covalent inhibitors at rates of up to 0.50% (EGFR) and 0.74% (ACHE) in 10,000-structure runs, with candidate structures achieving warhead-to-residue distances as short as 5.5 angstrom (EGFR) and 3.2 angstrom (ACHE) after further docking-based screening. More notably, the pipeline spontaneously generates structures bearing warhead motifs absent from the training data - including allenes, 3-oxo-

β

-sultams, and

α

-methylene-

β

-lactones - all of which have independent literature support as covalent warheads. These results suggest that RL-guided generation can explore covalent chemical space beyond its training distribution, and may be useful as a tool for medicinal chemists working on covalent drug discovery.

Renee Gil

Independent Researcher

Molecular Optimization Molecular Generation RL for Generative Models Drug Discovery

Apr 21, 2026

Structure-guided molecular design with contrastive 3D protein-ligand learning

Structure-based drug discovery faces the dual challenge of accurately capturing 3D protein-ligand interactions while navigating ultra-large chemical spaces to identify synthetically accessible candidates. In this work, we present a unified framework that addresses these challenges by combining contrastive 3D structure encoding with autoregressive molecular generation conditioned on commercial compound spaces. First, we introduce an SE(3)-equivariant transformer that encodes ligand and pocket structures into a shared embedding space via contrastive learning, achieving competitive results in zero-shot virtual screening. Second, we integrate these embeddings into a multimodal Chemical Language Model (MCLM). The model generates target-specific molecules conditioned on either pocket or ligand structures, with a learned dataset token that steers the output toward targeted chemical spaces, yielding candidates with favorable predicted binding properties across diverse targets.

Carles Navarro, Philipp Tholke, Gianni de Fabritiis

Acellera Labs, C/ Doctor Trueta 183, 08005 Barcelona, Spain · Computational Science Laboratory, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, 08003 Barcelona, Spain · Instituci´o Catalana de Recerca i Estudis Avan¸cats (ICREA), Passeig Llu´ıs Companys 23, 08010 Barcelona, Spain

Contrastive Learning Virtual Screening Structure-Based Drug Design 3D Molecular Generation 3D Representation Learning Molecular Generation+2

Apr 20, 2026

Predictive Modelling of Natural Medicinal Compounds for Alzheimer disease Using Machine Learning and Cheminformatics

Alzheimer disease (AD) is a neurodegenerative disease that lacks specific treatment options. Natural drugs have displayed neuroprotective effects; however, their high-throughput discovery is challenging because of the expense of experimental testing.The study proposed a machine learning approach to identify the anti-dementia activity of natural compounds based on molecular descriptors obtained from cheminformatics. The study used a set of active and inactive compounds obtained from public databases like ChEMBL and PubChem. Various molecular descriptors, including molecular weight, lipophilicity (LogP), topological polar surface area (TPSA), and hydrogen bonding descriptors, were calculated with RDKit. Data preprocessing and feature selection were applied, followed by the development of several classification models (Random Forest, XGBoost, Support Vector Machines, Logistic Regression) and their evaluation based on accuracy, precision, recall, F1-score and ROC-AUC. The outcome suggests that ensemble techniques, such as Random Forest, delivered the best predictive accuracy and ROC-AUC values. This study also highlights that critical physicochemical descriptors in particular lipophilicity, molecular weight and polarity are important in driving neuroprotective activity as identified by feature importance analysis. The integrated machine learning approach shows the potential of combining natural product research and machine learning in early drug discovery for dementia. They provide a means of rapidly exploring large datasets and selecting candidates for experimental confirmation, thus minimising costs and time in the development of drugs for neurodegenerative diseases.

Hafiza Syeda Yusra Tirmizi, Syed Ibad Hasnain, Muhammad Faris +2

Department of Biomedical Engineering Hamdard University Karachi, Pakistan. · Department of Computer Science and Engineering Malardalen University Västerås, Sweden.

Scientific Discovery Drug Discovery

Apr 19, 2026

Intervention-Aware Multiscale Representation Learning from Imaging Phenomics and Perturbation Transcriptomics

Microscopy-based phenotypic profiling is scalable for drug discovery but lacks the mechanistic depth of transcriptomics, which remains costly and scarce. Existing multimodal approaches either use images to support other modalities or naively align representations by sample identity, ignoring cell-type and dose variations in weakly paired data-limiting generalization to unseen interventions. In this paper, we introduce an intervention-aware distillation framework that leverages perturbational transcriptomics to guide image representation learning. A transcriptome-conditioned teacher integrates gene expression and intervention metadata to produce soft distributions over a chemistry-aware codebook organized by drug similarity. The teacher employs a fine-tuned single-cell foundation model to encode cell-type context and disentangle dose effects. An image-only student learns to predict these distributions from microscopy alone, distilling mechanistic knowledge while operating independently at test time. This design emphasizes intervention semantics rather than identity alignment and explicitly handles dose and cell-type mismatches. We provide theoretical guarantees showing that transcriptomic guidance tightens the risk bound for image-based prediction. On Cell Painting and RxRx datasets paired with L1000, our method significantly improves one-shot transfer to unseen interventions and drug-target gene discovery compared to self-supervised and alignment baselines.

Jiayuan Chen, Ruoqi Liu, Zishan Gu +1

The Ohio State University

Cross-Modal Knowledge Distillation Cross-Modal Representation Learning AI-Assisted Scientific Research Drug Discovery

Apr 17, 2026

KinetiDiff: Docking-Guided Diffusion for De Novo ACVR1 Inhibitor Design in Fibrodysplasia Ossificans Progressiva

We present KinetiDiff, a structure-based framework for de novo kinase inhibitor design that integrates a Geometry-Complete Diffusion Model with real-time AutoDock Vina gradient guidance. By injecting physics-based docking gradients into the diffusion denoising loop, KinetiDiff steers molecule generation toward high-affinity conformations for ACVR1 (ALK2), the causative kinase in Fibrodysplasia Ossificans Progressiva. From 10,000 diffusion samples, the framework produced 9,997 valid molecules. The best candidate achieved

-11.05

kcal/mol (pKd = 8.10), a 19.2% improvement over the crystallographic reference. The top 100 candidates all exceed the reference, with 100% Lipinski compliance, median synthetic accessibility of 2.67, and internal diversity of 0.790. Systematic ablation across four guidance strategies--Vina-Direct (physics), HNN-Denovo (neural proxy), multi-objective, and unguided--demonstrates that real-time docking guidance dominates on all metrics. We evaluate HNN-Denovo as a computationally efficient alternative (60-fold speedup per step), revealing a domain-mismatch limitation (r = 0.224 correlation with Vina) that explains its inferior performance. These results establish gradient-guided geometric diffusion as a practical approach for generating potent, synthetically accessible inhibitors against rare-disease kinase targets.

Aaryan Patel

Saugus High School, Santa Clarita, CA

Molecular Optimization Diffusion Guidance Structure-Based Drug Design Molecular Generation Drug Discovery

Apr 17, 2026

Evaluating the Progression of Large Language Model Capabilities for Small-Molecule Drug Design

Large Language Models (LLMs) have the potential to accelerate small molecule drug design due to their ability to reason about information from diverse sources and formats. However, their practical utility remains unclear due to the lack of benchmarks that reflect real-world scenarios. In this work, we introduce a suite of chemically-grounded tasks spanning molecular property prediction, molecular representation transformations, and molecular design. Importantly, we formulate these tasks as reinforcement learning (RL) environments, enabling a unified approach for evaluation and post-training. Across three model families, we find that frontier models are increasingly proficient at chemical tasks, but that there is significant room for improvement, especially in experimental settings with low data. Critically, we show that RL-based post-training can substantially improve performance. A smaller model post-trained on our environments becomes competitive with state-of-the-art frontier models, despite a significantly weaker base model. This suggests a practical route toward employing LLMs in drug discovery; by combining carefully-designed evaluation tasks with targeted post-training, we can both elucidate and close critical capability gaps.

Shriram Chennakesavalu, Kirill Shmilovich, Hayley Weir +5

Prescient Design, Genentech, South San Francisco, CA, USA

LLM Evaluation Molecular Property Prediction LLM Post-Training Drug Discovery

Apr 17, 2026

Large Language Models Meet Biomedical Knowledge Graphs for Mechanistically Grounded Therapeutic Prioritization

Drug repurposing is often framed as a candidate identification task, but existing approaches provide limited guidance for distinguishing biologically plausible candidates from historically well-connected ones. Here we introduce DrugKLM, a hybrid framework that integrates biomedical knowledge graph structure with large language model-based mechanistic reasoning to enable mechanistically grounded therapeutic prioritization. Across benchmark datasets, DrugKLM outperforms knowledge graph-only and language model-only baselines, including TxGNN. Beyond improved recall, DrugKLM confidence scores exhibit functional alignment with molecular phenotypes: higher scores are associated with transcriptional signatures linked to improved survival across 12 TCGA cancers. The scoring framework preferentially captures biologically perturbational signals rather than historical indication patterns. Expert curation across five cancers further reveals systematic differences in prioritization behavior, with DrugKLM elevating candidates supported by coherent mechanistic rationale and disease-specific clinical context. Together, these results establish DrugKLM as an evidence-integrative framework that translates heterogeneous biomedical data into mechanistically interpretable and clinically grounded therapeutic hypotheses.

Chih-Hsuan Wei, Chi-Ping Day, Zhizheng Wang +8

Division of Intramural Research (DIR), National Library of Medicine (NLM), National Institutes of Health (NIH); Bethesda, MD 20894, USA · Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20894, USA · Dartmouth Health, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA +2

LLM Grounding Large Language Model-Guided Scientific Discovery Knowledge Graphs Drug Discovery Biomedical KGs

Apr 17, 2026

An Interpretable Framework Applying Protein Words to Predict Protein-Small Molecule Complementary Pairing Rules

Despite the high accuracy of 'black box' deep learning models, drug discovery still relies on protein-ligand interaction principles and heuristics. To improve interpretability of protein-small molecule binding predictions, we developed the PWRules framework, which applies binding affinity data to identify privileged small molecule fragments and subsequently defines complementary pairing rules between these fragments and protein words (semantic sequence units) through an interpretability module. The resulting word-fragment rules are then ranked by the PWScore function to prioritize active compounds. Evaluations on benchmark datasets show that PWScore achieves competitive performance comparable to the physics-based model (Glide) and the deep learning model (PSICHIC) and shows broad applicability for protein targets outside the training dataset, e.g., SARS-CoV-2 main protease. Notably, PWScore captures complementary interaction information, yielding superior enrichment performance when integrated with these established methods. Structural analysis of protein-ligand complexes indicates that learned word-fragment rules are significantly enriched near ligand-binding pockets, despite training without explicit structural guidance. By extracting and applying complementary pairing rules, PWRules provides an interpretable framework for drug discovery.

Jingke Chen, Jingrui Zhong, Tazneen Hossain Tani +3

MOE Key Laboratory of Bioinformatics, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China

Protein-Ligand Binding Affinity Prediction Interpretable ML AI-Assisted Scientific Research Molecular Representation Learning Drug Discovery

Apr 12, 2026

PepBenchmark: A Standardized Benchmark for Peptide Machine Learning

Peptide therapeutics are widely regarded as the "third generation" of drugs, yet progress in peptide Machine Learning (ML) are hindered by the absence of standardized benchmarks. Here we present PepBenchmark, which unifies datasets, preprocessing, and evaluation protocols for peptide drug discovery. PepBenchmark comprises three components: (1) PepBenchData, a well-curated collection comprising 29 canonical-peptide and 6 non-canonical-peptide datasets across 7 groups, systematically covering key aspects of peptide drug development, representing, to the best of our knowledge, the most comprehensive AI-ready dataset resource to date; (2) PepBenchPipeline, a standardized preprocessing pipeline that ensures consistent dataset cleaning, construction, splitting, and feature transformation, mitigating quality issues common in ad hoc pipelines; and (3) PepBenchLeaderboard, a unified evaluation protocol and leaderboard with strong baselines across 4 major methodological families: Fingerprint-based, GNN-based, PLM-based, and SMILES-based models. Together, PepBenchmark provides the first standardized and comparable foundation for peptide drug discovery, facilitating methodological advances and translation into real-world applications. The data and code are publicly available at https://github.com/ZGCI-AI4S-Pep/PepBenchmark/.

Jiahui Zhang, Rouyi Wang, Kuangqi Zhou +4

Zhongguancun Academy · University of Science and Technology of China · Nankai University +1

Apr 10, 2026

Constraint-Aware Corrective Memory for Language-Based Drug Discovery Agents

Large language models are making autonomous drug discovery agents increasingly feasible, but reliable success in this setting is not determined by any single action or molecule. It is determined by whether the final returned set jointly satisfies protocol-level requirements such as set size, diversity, binding quality, and developability. This creates a fundamental control problem: the agent plans step by step, while task validity is decided at the level of the whole candidate set. Existing language-based drug discovery systems therefore tend to rely on long raw history and under-specified self-reflection, making failure localization imprecise and planner-facing agent states increasingly noisy. We present CACM (Constraint-Aware Corrective Memory), a language-based drug discovery framework built around precise set-level diagnosis and a concise memory write-back mechanism. CACM introduces protocol auditing and a grounded diagnostician, which jointly analyze multimodal evidence spanning task requirements, pocket context, and candidate-set evidence to localize protocol violations, generate actionable remediation hints, and bias the next action toward the most relevant correction. To keep planning context compact, CACM organizes memory into static, dynamic, and corrective channels and compresses them before write-back, thereby preserving persistent task information while exposing only the most decision-relevant failures. Our experimental results show that CACM improves the target-level success rate by 36.4% over the state-of-the-art baseline. The results show that reliable language-based drug discovery benefits not only from more powerful molecular tools, but also from more precise diagnosis and more economical agent states.

Maochen Sun, Youzhi Zhang, Gaofeng Meng

Institute of Automation, Chinese Academy of Sciences, China · School of Advanced Interdisciplinary Sciences, University of Chinese Academy of Sciences, China · Centre for Artificial Intelligence and Robotics, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, China

Drug Discovery Memory-Augmented Language Model Agents Large Language Model-Guided Scientific Discovery LLM Self-Correction

Apr 8, 2026

Predicting Activity Cliffs for Autonomous Medicinal Chemistry

Activity cliff prediction - identifying positions where small structural changes cause large potency shifts - has been a persistent challenge in computational medicinal chemistry. This work focuses on a parsimonious definition: which small modifications, at which positions, confer the highest probability of an outcome change. Position-level sensitivity is calculated using 25 million matched molecular pairs from 50 ChEMBL targets across six protein families, revealing that two questions have fundamentally different answers. "Which positions vary most?" is answered by scaffold size alone (NDCG@3 = 0.966), requiring no machine learning. "Which are true activity cliffs?" - where small modifications cause disproportionately large effects, as captured by SALI normalization - requires an 11-feature model with 3D pharmacophore context (NDCG@3 = 0.910 vs. 0.839 random), generalizing across all six protein families, novel scaffolds (0.913), and temporal splits (0.878). The model identifies the cliff-prone position first 53% of the time (vs. 27% random - 2x lift), reducing positions a chemist must explore from 3.1 to 2.1 - a 31% reduction in first-round experiments. Predicting which modification to make is not tractable from structure alone (Spearman 0.268, collapsing to -0.31 on novel scaffolds). The system is released as open-source code and an interactive webapp.

Michael Cuccarese

Drug Discovery Molecular Property Prediction

Apr 8, 2026

Rhizome OS-1: Rhizome's Semi-Autonomous Operating System for Small Molecule Drug Discovery

We present Rhizome OS-1, a semi-autonomous operating system for small molecule drug discovery in which multi-modal AI agents operate as a full multidisciplinary discovery team. These agents function as computational chemists, medicinal chemists, and patent agents: they write and execute analysis code (fingerprint clustering, R-group decomposition, substructure search), visually triage molecular grids using vision capabilities, formulate explicit medicinal chemistry hypotheses across three strategy tiers, assess patent freedom-to-operate, and dynamically adapt generation strategies based on empirical screening feedback. Powered by r1 - a 246M-parameter graph diffusion model trained on 800 million molecular graphs - the system generates novel chemical matter directly on molecular graphs using fragment masking, scaffold decoration, linker design, and graph editing primitives. In two oncology campaigns (BCL6 BTB domain and EZH2 SET domain), the agent team executed 26 seeds and produced 5,231 novel molecules. Across both targets, 91.9% of generated Murcko scaffolds are absent from ChEMBL, with median Tanimoto similarity of 0.56-0.69 to the nearest known active. Boltz-2 binding affinity predictions, calibrated against ChEMBL data, achieved Spearman correlations of -0.53 to -0.64 and ROC AUC values of 0.88-0.93. These results demonstrate that semi-autonomous agent systems, equipped with graph-native generative tools and physics-informed scoring, enable a new paradigm for early-stage drug discovery: scaled, rapid, and adaptive inverse design with embedded medicinal chemistry reasoning.

Yiwen Wang, Gregory Sinenka, Xhuliano Brace

Rhizome Research Inc.

Drug Discovery Autonomous Research Agents Molecular Graph Generation

Apr 2, 2026

MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization

Computational drug discovery, particularly the complex workflows of drug molecule screening and optimization, requires orchestrating dozens of specialized tools in multi-step workflows, yet current AI agents struggle to maintain robust performance and consistently underperform in these high-complexity scenarios. Here we present MolClaw, an autonomous agent that leads drug molecule evaluation, screening, and optimization. It unifies over 30 specialized domain resources through a three-tier hierarchical skill architecture (70 skills in total) that facilitates agent long-term interaction at runtime: tool-level skills standardize atomic operations, workflow-level skills compose them into validated pipelines with quality check and reflection, and a discipline-level skill supplies scientific principles governing planning and verification across all scenarios in the field. Additionally, we introduce MolBench, a benchmark comprising molecular screening, optimization, and end-to-end discovery challenges spanning 8 to 50+ sequential tool calls. MolClaw achieves state-of-the-art performance across all metrics, and ablation studies confirm that gains concentrate on tasks that demand structured workflows while vanishing on those solvable with ad hoc scripting, establishing workflow orchestration competence as the primary capability bottleneck for AI-driven drug discovery.

Lisheng Zhang, Lilong Wang, Xiangyu Sun +14

Peking University Health Science Center, Peking University, Beijing, China · Shanghai AI Laboratory, Shanghai, China · Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

Drug Discovery Autonomous Research Agents Molecular Optimization LLM Agent Orchestration AI Agent Benchmarks Agent Skill Learning

Mar 30, 2026

ChemCLIP: Bridging Organic and Inorganic Anticancer Compounds Through Contrastive Learning

The discovery of anticancer therapeutics has traditionally treated organic small molecules and metal-based coordination complexes as separate chemical domains, limiting knowledge transfer despite their shared biological objectives. This disparity is particularly pronounced in available data, with extensive screening databases for organic compounds compared to only a few thousand characterized metal complexes. Here, we introduce ChemCLIP, a dual-encoder contrastive learning framework that bridges this organic-inorganic divide by learning unified representations based on shared anticancer activities rather than structural similarity. We compiled complementary datasets comprising 44,854 unique organic compounds and 5,164 unique metal complexes, standardized across 60 cancer cell lines. By training parallel encoders with activity-aware hard negative mining, we mapped structurally distinct compounds into a shared 256-dimensional embedding space where biologically similar compounds cluster together regardless of chemical class. We systematically evaluated four molecular encoding strategies: Morgan fingerprints, ChemBERTa, MolFormer, and Chemprop, through quantitative alignment metrics, embedding visualizations, and downstream classification tasks. Morgan fingerprints achieved superior performance with an average alignment ratio of 0.899 and downstream classification AUCs of 0.859 (inorganic) and 0.817 (organic). This work establishes contrastive learning as an effective strategy for unifying disparate chemical domains and provides empirical guidance for encoder selection in multi-modal chemistry applications, with implications extending beyond anticancer drug discovery to any scenario requiring cross-domain chemical knowledge transfer.

Mohamad Koohi-Moghadam, Hongzhe Sun, Hongyan Li +1

Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam Road, Hong Kong SAR, PR China · Department of Chemistry, The University of Hong Kong, Pok Fu Lam Road, Hong Kong S.A.R., PRC

Cancer Drug Response Prediction Molecular Representation Learning Drug Discovery Contrastive Learning

Mar 27, 2026

DPD-Cancer: Explainable Graph-Based Deep Learning for Small Molecule Anti-Cancer Activity Prediction

DPD-Cancer is a graph-attention deep learning framework for predicting small-molecule DPD-Cancer is a graph-attention deep learning framework for predicting small-molecule anti-cancer activity across the NCI-60 panel, trained and evaluated under a strict chemistry-aware data-partitioning scheme. On the hold-out test set, the classifier achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) of 0.87 (95% CI [0.86, 0.88]) and Area Under the Precision-Recall Curve (AUPRC) of 0.73 (95% CI [0.70, 0.76]); per-cell-line regression models for 73 cell lines produced a median Pearson's Correlation Coefficient (Pearson's R) of 0.64 and median Root Mean Squared Error (RMSE) of 0.67 for pGI50-value prediction. Benchmarks against pdCSM-Cancer, MLASM, and ACLPred under matched data conditions yielded consistently higher Matthew's Correlation Coefficient (MCC) scores, an occlusion-based attribution analysis confirmed that model explanations were quantitatively faithful to classifier decisions, and an applicability-domain analysis characterised reliability as a function of chemical distance. To facilitate widespread adoption, DPD-Cancer is available as a free, user-friendly web server for unrestricted use at https://biosig.lab.uq.edu.au/dpd_cancer/.

Magnus H. Strømme, Alex G. C. de Sá, David B. Ascher

The Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, 4072, Australia · Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Victoria, 3004, Australia

Cancer Drug Response Prediction Molecular Property Prediction Drug Discovery

Mar 20, 2026

G2DR: A Genotype-First Framework for Genetics-Informed Target Prioritization and Drug Repurposing

Human genetics offers a promising route to therapeutic discovery, yet practical frameworks translating genotype-derived signal into ranked target and drug hypotheses remain limited, particularly when matched disease transcriptomics are unavailable. Here we present G2DR, a genotype-first prioritization framework propagating inherited variation through genetically predicted expression, multi-method gene-level testing, pathway enrichment, network context, druggability, and multi-source drug--target evidence integration. In a migraine case study with 733 UK Biobank participants under stratified five-fold cross-validation, we imputed expression across seven transcriptome-weight resources and ranked genes using a reproducibility-aware discovery score from training and validation data, followed by a balanced integrated score for target selection. Discovery-based prioritization generalized to held-out data, achieving gene-level ROC-AUC of 0.775 and PR-AUC of 0.475, while retaining enrichment for curated migraine biology. Mapping prioritized genes to compounds via Open Targets, DGIdb, and ChEMBL yielded drug sets enriched for migraine-linked compounds relative to a global background, though recovery favoured broader mechanism-linked and off-label space over migraine-specific approved therapies. Directionality filtering separated broadly recovered compounds from mechanistically compatible candidates. G2DR is a modular framework for genetics-informed hypothesis generation, not a clinically actionable recommendation system. All outputs require independent experimental, pharmacological, and clinical validation.

Muhammad Muneeb, David B. Ascher

School of Chemistry and Molecular Biology, The University of Queensland, Queen Street, 4067, Queensland, Australia · Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Commercial Road, 3004, Victoria, Australia

Drug Discovery Scientific Hypothesis Generation Genomics

Mar 19, 2026

BVSIMC: Bayesian Variable Selection-Guided Inductive Matrix Completion for Improved and Interpretable Drug Discovery

Recent advances in drug discovery have demonstrated that incorporating side information (e.g., chemical properties about drugs and genomic information about diseases) often greatly improves prediction performance. However, these side features can vary widely in relevance and are often noisy and high-dimensional. We propose Bayesian Variable Selection-Guided Inductive Matrix Completion (BVSIMC), a new Bayesian model that enables variable selection from side features in drug discovery. By learning sparse latent embeddings, BVSIMC improves both predictive accuracy and interpretability. We validate our method through simulation studies and two drug discovery applications: 1) prediction of drug resistance in Mycobacterium tuberculosis, and 2) prediction of new drug-disease associations in computational drug repositioning. On both synthetic and real data, BVSIMC outperforms several other state-of-the-art methods in terms of prediction. In our two real examples, BVSIMC further reveals the most clinically meaningful side features.

Sijian Fan, Liyan Xiong, Dayuan Wang +2

Department of Statistics, George Mason University

Robust Matrix Completion Drug Discovery Feature Selection

Mar 18, 2026

The Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery

Integrating quantum mechanics into drug discovery marks a decisive shift from empirical trial-and-error toward quantitative precision. However, the prohibitive cost of ab initio molecular dynamics has historically forced a compromise between chemical accuracy and computational scalability. This paper identifies the convergence of High-Performance Computing (HPC), Machine Learning (ML), and Quantum Computing (QC) as the definitive solution to this bottleneck. While ML foundation models, such as FeNNix-Bio1, enable quantum-accurate simulations, they remain tethered to the inherent limits of classical data generation. We detail how High-Performance Quantum Computing (HPQC), utilizing hybrid QPU-GPU architectures, will serve as the ultimate accelerator for quantum chemistry data. By leveraging Hilbert space mapping, these systems can achieve true chemical accuracy while bypassing the heuristics of classical approximations. We show how this tripartite convergence optimizes the drug discovery pipeline, spanning from initial system preparation to ML-driven, high-fidelity simulations. Finally, we position quantum-enhanced sampling as the beyond GPU frontier for modeling reactive cellular systems and pioneering next-generation materials.

Narjes Ansari, César Feniou, Nicolaï Gouraud +13

Qubit Pharmaceuticals, Advanced Research Department, 75014 Paris, France · Qubit Pharmaceuticals Inc, Advanced Research Department, Chicago, IL, USA · Sorbonne Université, Laboratoire de Chimie Théorique, UMR 7616 CNRS, 75005 Paris, France

Drug Discovery Quantum Chemistry High-Performance Computing

Mar 16, 2026

Empowering Chemical Structures with Biological Insights for Scalable Phenotypic Virtual Screening

Motivation: The scalable identification of bioactive compounds is essential for contemporary drug discovery. This process faces a key trade-off: structural screening offers scalability but lacks biological context, whereas high-content phenotypic profiling provides deep biological insights but is resource-intensive. The primary challenge is to extract robust biological signals from noisy data and encode them into representations that do not require biological data at inference. Results: This study presents DECODE (DEcomposing Cellular Observations of Drug Effects), a framework that bridges this gap by empowering chemical representations with intrinsic biological semantics to enable structure-based in silico biological profiling. DECODE leverages limited paired transcriptomic and morphological data as supervisory signals during training, enabling the extraction of a measurement-invariant biological fingerprint from chemical structures and explicit filtering of experimental noise. Our evaluations demonstrate that DECODE retrieves functionally similar drugs in zero-shot settings with over 20% relative improvement over chemical baselines in mechanism-of-action (MOA) prediction. Furthermore, the framework achieves a 6-fold increase in hit rates for novel anti-cancer agents during external validation. Availability and implementation: The codes and datasets of DECODE are available at https://github.com/lian-xiao/DECODE.

Xiaoqing Lian, Pengsen Ma, Tengfeng Ma +9

State Key Laboratory of Chemo and Biosensing, College of Computer Science and Electronic Engineering; The Ministry of Education Key Laboratory of Fusion Computing of Supercomputing and Artificial Intelligence, Hunan University, 410082, Changsha, China · School of Artificial Intelligence and Computer Science, Jiangnan University, 214122, Wuxi, China · Department of Computer Science, University of Tsukuba, Tsukuba, Ibaraki, Japan +2

Virtual Screening Drug Discovery Molecular Representation Learning

Mar 13, 2026

Deciphering Scientific Reasoning Steps from Outcome Data for Molecule Optimization

Emerging reasoning models hold promise for automating scientific discovery. However, their training is hindered by a critical supervision gap: experimental outcomes are abundant, whereas intermediate reasoning steps are rarely documented at scale. To bridge this gap, we propose DESRO, a framework for deciphering scientific reasoning from outcomes. By analyzing shared patterns and key differences within grouped data, a large language model (LLM) can recover the underlying logic. We instantiate this framework in molecule optimization, a pivotal stage in drug discovery that traditionally relies on the iterative reasoning of medicinal chemists. Across 2.3 million molecular property records, our framework infers optimization rationales by grouping molecules with shared fragments, then using an LLM to analyze how structural variations correlate with property differences. Based on the derived data, we train a model that conducts molecule optimization through an interpretable reasoning process. DESRO achieves the highest success rates on 15 out of 18 tasks, spanning both single- and multi-property optimization of bioactivity and ADMET properties. The reasoning process enables robust generalization to out-of-distribution scenarios, including novel property combinations, unseen biological targets, and unseen properties defined solely by natural language descriptions. In retrospective case studies under strict temporal splits, the model autonomously reconstructs expert-level lead optimization trajectories. Additionally, our framework extends beyond molecule optimization to reaction ligand selection. Our results establish deciphering reasoning steps from outcome data as a viable paradigm for enabling scientific reasoning, providing a scalable approach to accelerate scientific discovery.

Zequn Liu, Kehan Wu, Shufang Xie +5

Zhongguancun Academy · School of Computer Science and Technology, University of Science and Technology of China · Global Health Drug Discovery Institute

Scientific Reasoning in Language Models Molecular Optimization Large Language Model-Guided Optimization LLM Reasoning Drug Discovery

Mar 11, 2026

Co-Diffusion: An Affinity-Aware Two-Stage Latent Diffusion Framework for Generalizable Drug-Target Affinity Prediction

Predicting drug-target affinity is fundamental to virtual screening and lead optimization. However, existing deep models often suffer from representation collapse in stringent cold-start regimes, where the scarcity of labels and domain shifts prevent the learning of transferable pharmacophores and binding motifs. In this paper, we propose Co-Diffusion, a novel affinity-aware framework that redefines DTA prediction as a constrained latent denoising process to enhance generalization. Co-Diffusion employs a two-stage paradigm: Stage I establishes an affinity-steered latent manifold by aligning drug and target embeddings under an explicit supervised objective, ensuring that the latent space reflects the intrinsic binding landscape. Stage II introduces modality-specific latent diffusion as a stochastic perturb-and-denoise regularizer, forcing the model to recover consistent affinity semantics from noisy structural representations. This approach effectively mitigates the reconstruction-regression conflict common in generative DTA models. Theoretically, we show that Co-Diffusion maximizes a variational lower bound on the joint likelihood of drug structures, protein sequences, and binding strength. Extensive experiments across multiple benchmarks demonstrate that Co-Diffusion significantly outperforms state-of-the-art baselines, particularly yielding superior zero-shot generalization on unseen molecular scaffolds and novel protein families-paving a robust path for in silico drug prioritization in unexplored chemical spaces.

Yining Qian, Pengjie Wang, Yixiao Li +4

School of Computer Science and Engineering, Northeastern University, Shenyang 110819, China · College of Information Science and Engineering, Northeastern University, Shenyang 110819, China · Westlake University, Hangzhou 310000, China +2

Drug Discovery Latent Diffusion Models

Mar 7, 2026

ConfHit: Conformal Generative Design with Oracle Free Guarantees

The success of deep generative models in scientific discovery requires not only the ability to generate novel candidates but also reliable guarantees that these candidates indeed satisfy desired properties. Recent conformal-prediction methods offer a path to such guarantees, but its application to generative modeling in drug discovery is limited by budget constraints, lack of oracle access, and distribution shift. To this end, we introduce ConfHit, a distribution-free framework that provides validity guarantees under these conditions. ConfHit formalizes two central questions: (i) Certification: whether a generated batch can be guaranteed to contain at least one hit with a user-specified confidence level, and (ii) Design: whether the generation can be refined to a compact set without weakening this guarantee. ConfHit leverages weighted exchangeability between historical and generated samples to eliminate the need for an experimental oracle, constructs multiple-sample density-ratio weighted conformal p-value to quantify statistical confidence in hits, and proposes a nested testing procedure to certify and refine candidate sets of multiple generated samples while maintaining statistical guarantees. Across representative generative molecule design tasks and a broad range of methods, ConfHit consistently delivers valid coverage guarantees at multiple confidence levels while maintaining compact certified sets, establishing a principled and reliable framework for generative modeling.

Siddhartha Laghuvarapu, Ying Jin, Jimeng Sun

Siebel School of Computing and Data Science, University of Illinois Urbana-Champaign, IL, USA · Department of Statistics and Data Science, Wharton School, University of Pennysylvania, PA, USA

Molecular Generation Weighted Conformal Prediction Drug Discovery Distribution Shift

Mar 5, 2026

FuseDiff: Symmetry-Preserving Joint Diffusion for Dual-Target Structure-Based Drug Design

Dual-target structure-based drug design aims to generate a single ligand together with two pocket-specific binding poses, each compatible with a corresponding target pocket, enabling polypharmacological therapies with improved efficacy and reduced resistance. Existing approaches typically rely on staged pipelines, which either decouple the two poses via conditional-independence assumptions or enforce overly rigid correlations, and therefore fail to jointly generate two target-specific binding modes. To address this, we propose FuseDiff, an end-to-end diffusion model that jointly generates a ligand molecular graph and two pocket-specific binding poses conditioned on both pockets. FuseDiff features a message-passing backbone with Dual-target Local Context Fusion (DLCF), which fuses each ligand atom's local context from both pockets to enable expressive joint modeling while preserving the desired symmetries. Together with explicit bond generation, FuseDiff enforces topological consistency across the two poses under a shared graph while allowing target-specific geometric adaptation in each pocket. To support principled training and evaluation, we derive a dual-target training set and use an independent held-out test set for evaluation. Experiments on the benchmark and a real-world dual-target system show that FuseDiff achieves state-of-the-art docking performance and enables the first systematic assessment of dual-target pose quality prior to docking-based pose search.

Jianliang Wu, Anjie Qiao, Zhen Wang +2

School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou, China · School of Computer Science and Engineering, Guangdong Province Key Laboratory of Computational Science, Sun Yat-sen University, Guangzhou, China · Gaoling School of Artificial Intelligence, Renmin University of China, Beijing, China +1

Structure-Based Drug Design Drug Discovery 3D Molecular Generation Molecular Graph Generation Conditional Diffusion Models

Mar 4, 2026

Mozi: Governed Autonomy for Drug Discovery LLM Agents

Tool-augmented large language model (LLM) agents promise to unify scientific reasoning with computation, yet their deployment in high-stakes domains like drug discovery is bottlenecked by two critical barriers: unconstrained tool-use governance and poor long-horizon reliability. In dependency-heavy pharmaceutical pipelines, autonomous agents often drift into irreproducible trajectories, where early-stage hallucinations multiplicatively compound into downstream failures. To overcome this, we present Mozi, a dual-layer architecture that bridges the flexibility of generative AI with the deterministic rigor of computational biology. Layer A (Control Plane) establishes a governed supervisor--worker hierarchy that enforces role-based tool isolation, limits execution to constrained action spaces, and drives reflection-based replanning. Layer B (Workflow Plane) operationalizes canonical drug discovery stages -- from Target Identification to Lead Optimization -- as stateful, composable skill graphs. This layer integrates strict data contracts and strategic human-in-the-loop (HITL) checkpoints to safeguard scientific validity at high-uncertainty decision boundaries. Operating on the design principle of ``free-form reasoning for safe tasks, structured execution for long-horizon pipelines,'' Mozi provides built-in robustness mechanisms and trace-level audibility to completely mitigate error accumulation. We evaluate Mozi on PharmaBench, a curated benchmark for biomedical agents, demonstrating superior orchestration accuracy over existing baselines. Furthermore, through end-to-end therapeutic case studies, we demonstrate Mozi's ability to navigate massive chemical spaces, enforce stringent toxicity filters, and generate highly competitive in silico candidates, effectively transforming the LLM from a fragile conversationalist into a reliable, governed co-scientist.

He Cao, Siyu Liu, Fan Zhang +7

AI Agents for Scientific Discovery LLM Agent Orchestration Long-Horizon LLM Agents AI Agent Governance Drug Discovery

Mar 3, 2026

MMAI Gym for Science: Training Liquid Foundation Models for Drug Discovery

General-purpose large language models (LLMs) that rely on in-context learning do not reliably deliver the scientific understanding and performance required for drug discovery tasks. Simply increasing model size or introducing reasoning tokens does not yield significant performance gains. To address this gap, we introduce the MMAI Gym for Science, a one-stop shop molecular data formats and modalities as well as task-specific reasoning, training, and benchmarking recipes designed to teach foundation models the 'language of molecules' in order to solve practical drug discovery problems. We use MMAI Gym to train an efficient Liquid Foundation Model (LFM) for these applications, demonstrating that smaller, purpose-trained foundation models can outperform substantially larger general-purpose or specialist models on molecular benchmarks. Across essential drug discovery tasks - including molecular optimization, ADMET property prediction, retrosynthesis, drug-target activity prediction, and functional group reasoning - the resulting model achieves near specialist-level performance and, in the majority of settings, surpasses larger models, while remaining more efficient and broadly applicable in the domain.

Maksim Kuznetsov, Zulfat Miftahutdinov, Rim Shayakhmetov +17

Insilico Medicine · Liquid AI

Molecular Optimization Molecular Property Prediction Molecular Foundation Models Retrosynthesis Molecular Representation Learning Drug Discovery

Mar 2, 2026

On the Reliability of AI Methods in Drug Discovery: Evaluation of Boltz-2 for Structure and Binding Affinity Prediction

Despite continuing hype about the role of AI in drug discovery, no "AI-discovered drugs" have so far received regulatory approval. Here we assess one of the latest AI based tools in this domain. The ability to rapidly predict protein-ligand structures and binding affinities is pivotal for accelerating drug discovery. Boltz-2, a recently developed biomolecular foundation model, aims to bridge the gap between AI efficiency and physics-based precision through a joint "co-folding" approach. In this study, we provide an extensive evaluation of Boltz-2 using two large-scale datasets: 16,780 compounds for 3CLPro and 21,702 compounds for TNKS2. We compare Boltz-2 predicted structures with traditional docking and binding affinities with binding free energies derived from the physics-based ESMACS protocol. Structural analysis reveals significant global RMSD variations, indicating that Boltz-2 predicts multiple protein conformations and ligand binding positions rather than a single converged pose. Energetic evaluations exhibit only weak to moderate correlations across the global datasets. Furthermore, a focused analysis of the top 100 compounds yields no significant correlation between the Boltz-2 predictions and the binding free energies from fine-grained ESMACS, alongside observed saturation difference in ligand structures. Our results show that while Boltz-2 offers substantial speed for initial screening, it lacks the energetic resolution required for lead identification. These findings highlight the necessity of employing physics-based methods for the reliability and refinement of AI-derived models.

Shunzhou Wan, Xibei Zhang, Xiao Xue +1

Centre for Computational Science, University College London, London, WC1H 0AJ, U.K. · Advanced Research Computing Centre, University College London, London, WC1H 0AJ, U.K.

Protein-Ligand Binding Affinity Prediction Drug Discovery Structure-Based Drug Design

Feb 28, 2026

From Literature to Hypotheses: An AI Co-Scientist System for Biomarker-Guided Drug Combination Hypothesis Generation

The rapid growth of biomedical evidence makes it difficult to translate biomarker mechanisms into actionable drug combination hypotheses. We present CoDHy, an interactive AI co-scientist for biomarker-guided hypothesis generation in oncology. CoDHy constructs task-specific knowledge graphs from curated databases and biomedical literature, then combines graph embeddings with agent-based reasoning to generate, validate, and rank evidence-grounded drug combinations. Through a web interface, researchers specify the biomarker, cancer context, and literature scope; inspect supporting evidence and intermediate results; and iteratively refine the generated hypotheses. The demonstration presents CoDHy's end-to-end workflow and shows how researchers can interactively explore and compare mechanistically supported drug combinations while remaining in control of hypothesis prioritization.

Raneen Younis, Suvinava Basak, Lukas Chavez +1

Peter L. Reichertz Institute for Medical Informatics (PLRI), Hannover Medical School · Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine (CAIMed) · Sanford Burnham Prebys (SBP) Medical Discovery Institute

Scientific Hypothesis Generation Oncology Drug Discovery Biomedical KGs

Feb 26, 2026

Complex Networks and the Drug Repositioning Problem

In this Master's thesis, the graph properties of a multi-level drug-protein network are studied, as well as how the network's shape has informed discoveries over the years, identifying primarily crawling discoveries and a smaller number of hopping discoveries. Finally, the network structure is used to inform a network diffusion recommendation system and to prioritize existing drugs for repurposing against proteins in organisms that cause Neglected Tropical Diseases.

Felipe Bivort Haiek

Faculty of Exact and Natural Sciences University of Buenos Aires

Drug Discovery Healthcare

Feb 18, 2026

Retrieval-Augmented Foundation Models for Matched Molecular Pair Transformations to Recapitulate Medicinal Chemistry Intuition

Matched molecular pairs (MMPs) capture the local chemical edits that medicinal chemists routinely use to design analogs, but existing ML approaches either operate at the whole-molecule level with limited edit controllability or learn MMP-style edits from restricted settings and small models. We propose a variable-to-variable formulation of analog generation and train a foundation model on large-scale MMP transformations (MMPTs) to generate diverse variables conditioned on an input variable. To enable practical control, we develop prompting mechanisms that let the users specify preferred transformation patterns during generation. We further introduce MMPT-RAG, a retrieval-augmented framework that uses external reference analogs as contextual guidance to steer generation and generalize from project-specific series. Experiments on general chemical corpora and patent-specific datasets demonstrate improved diversity, novelty, and controllability, and show that our method recovers realistic analog structures in practical discovery scenarios.

Bo Pan, Peter Zhiping Zhang, Hao-Wei Pang +4

Department of Computer Science, Emory University, Atlanta, GA, USA · Merck & Co., Inc., Rahway, NJ, USA

Molecular Generation Drug Discovery Molecular Optimization